Literature DB >> 30065221

Engineering Cocrystals of PoorlyWater-Soluble Drugs to Enhance Dissolution in Aqueous Medium.

Indumathi Sathisaran1, Sameer Vishvanath Dalvi2.   

Abstract

Biopharmaceutics Classification System (BCS) Class II and IV drugs suffer from poor aqueous solubility and hence low bioavailability. Most of these drugs are hydrophobic and cannot be developed into a pharmaceutical formulation due to their poor aqueous solubility. One of the ways to enhance the aqueous solubility of poorlywater-soluble drugs is to use the principles of crystal engineering to formulate cocrystals of these molecules with water-soluble molecules (which are generally called coformers). Many researchers have shown that the cocrystals significantly enhance the aqueous solubility of poorly water-soluble drugs. In this review, we present a consolidated account of reports available in the literature related to the cocrystallization of poorly water-soluble drugs. The current practice to formulate new drug cocrystals with enhanced solubility involves a lot of empiricism. Therefore, in this work, attempts have been made to understand a general framework involved in successful (and unsuccessful) cocrystallization events which can yield different solid forms such as cocrystals, cocrystal polymorphs, cocrystal hydrates/solvates, salts, coamorphous solids, eutectics and solid solutions. The rationale behind screening suitable coformers for cocrystallization has been explained based on the rules of five i.e., hydrogen bonding, halogen bonding (and in general non-covalent bonding), length of carbon chain, molecular recognition points and coformer aqueous solubility. Different techniques to screen coformers for effective cocrystallization and methods to synthesize cocrystals have been discussed. Recent advances in technologies for continuous and solvent-free production of cocrystals have also been discussed. Furthermore, mechanisms involved in solubilization of these solid forms and the parameters influencing dissolution and stability of specific solid forms have been discussed. Overall, this review provides a consolidated account of the rationale for design of cocrystals, past efforts, recent developments and future perspectives for cocrystallization research which will be extremely useful for researchers working in pharmaceutical formulation development.

Entities:  

Keywords:  cocrystals; coformers; crystal engineering; dissolution enhancement; eutectics; hydrogen bonding; polymorphism; poorly water-soluble

Year:  2018        PMID: 30065221      PMCID: PMC6161265          DOI: 10.3390/pharmaceutics10030108

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  115 in total

1.  Combining piracetam and lithium salts: ionic co-crystals and co-drugs?

Authors:  Dario Braga; Fabrizia Grepioni; Lucia Maini; Davide Capucci; Saverio Nanna; Johan Wouters; Luc Aerts; Luc Quéré
Journal:  Chem Commun (Camb)       Date:  2012-07-10       Impact factor: 6.222

2.  Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids.

Authors:  Scott L Childs; Leonard J Chyall; Jeanette T Dunlap; Valeriya N Smolenskaya; Barbara C Stahly; G Patrick Stahly
Journal:  J Am Chem Soc       Date:  2004-10-20       Impact factor: 15.419

3.  Antioxidant-Based Eutectics of Irbesartan: Viable Multicomponent Forms for the Management of Hypertension.

Authors:  Jamshed Haneef; Renu Chadha
Journal:  AAPS PharmSciTech       Date:  2017-12-15       Impact factor: 3.246

4.  Influence of Coformer Stoichiometric Ratio on Pharmaceutical Cocrystal Dissolution: Three Cocrystals of Carbamazepine/4-Aminobenzoic Acid.

Authors:  Zi Li; Adam J Matzger
Journal:  Mol Pharm       Date:  2016-02-03       Impact factor: 4.939

Review 5.  Use of pharmaceutical salts and cocrystals to address the issue of poor solubility.

Authors:  David P Elder; René Holm; Heidi Lopez de Diego
Journal:  Int J Pharm       Date:  2012-11-24       Impact factor: 5.875

6.  Improving co-amorphous drug formulations by the addition of the highly water soluble amino Acid, proline.

Authors:  Katrine Tarp Jensen; Korbinian Löbmann; Thomas Rades; Holger Grohganz
Journal:  Pharmaceutics       Date:  2014-07-14       Impact factor: 6.321

7.  Mechanistic Analysis of Cocrystal Dissolution as a Function of pH and Micellar Solubilization.

Authors:  Fengjuan Cao; Gordon L Amidon; Nair Rodriguez-Hornedo; Gregory E Amidon
Journal:  Mol Pharm       Date:  2016-02-15       Impact factor: 4.939

Review 8.  The Halogen Bond.

Authors:  Gabriella Cavallo; Pierangelo Metrangolo; Roberto Milani; Tullio Pilati; Arri Priimagi; Giuseppe Resnati; Giancarlo Terraneo
Journal:  Chem Rev       Date:  2016-01-26       Impact factor: 60.622

9.  Improving lithium therapeutics by crystal engineering of novel ionic cocrystals.

Authors:  Adam J Smith; Seol-Hee Kim; Naga K Duggirala; Jingji Jin; Lukasz Wojtas; Jared Ehrhart; Brian Giunta; Jun Tan; Michael J Zaworotko; R Douglas Shytle
Journal:  Mol Pharm       Date:  2013-11-18       Impact factor: 4.939

10.  Hydrogen bonding vs. halogen bonding: the solvent decides.

Authors:  Craig C Robertson; James S Wright; Elliot J Carrington; Robin N Perutz; Christopher A Hunter; Lee Brammer
Journal:  Chem Sci       Date:  2017-06-01       Impact factor: 9.825

View more
  15 in total

1.  Levofloxacin Cocrystal/Salt with Phthalimide and Caffeic Acid as Promising Solid-State Approach to Improve Antimicrobial Efficiency.

Authors:  Noor Ul Islam; Muhammad Naveed Umar; Ezzat Khan; Fakhria A Al-Joufi; Shaymaa Najm Abed; Muhammad Said; Habib Ullah; Muhammad Iftikhar; Muhammad Zahoor; Farhat Ali Khan
Journal:  Antibiotics (Basel)       Date:  2022-06-13

2.  Superior Dissolution Behavior and Bioavailability of Pharmaceutical Cocrystals and Recent Regulatory Issues.

Authors:  Meng Y Xia; Bing Q Zhu; Jian-R Wang; Ze E Yang; Xue F Mei
Journal:  ACS Med Chem Lett       Date:  2021-12-30       Impact factor: 4.345

Review 3.  Periodic DFT Calculations-Review of Applications in the Pharmaceutical Sciences.

Authors:  Anna Helena Mazurek; Łukasz Szeleszczuk; Dariusz Maciej Pisklak
Journal:  Pharmaceutics       Date:  2020-05-01       Impact factor: 6.321

4.  Quality by Design Optimization of Cold Sonochemical Synthesis of Zidovudine-Lamivudine Nanosuspensions.

Authors:  Bwalya A Witika; Vincent J Smith; Roderick B Walker
Journal:  Pharmaceutics       Date:  2020-04-17       Impact factor: 6.321

5.  Drug Solubility Enhancement through the Preparation of Multicomponent Organic Materials: Eutectics of Lovastatin with Carboxylic Acids.

Authors:  Andrea Mariela Araya-Sibaja; José Roberto Vega-Baudrit; Teodolito Guillén-Girón; Mirtha Navarro-Hoyos; Silvia Lucia Cuffini
Journal:  Pharmaceutics       Date:  2019-03-09       Impact factor: 6.321

Review 6.  Amino Acids as the Potential Co-Former for Co-Crystal Development: A Review.

Authors:  Ilma Nugrahani; Maria Anabella Jessica
Journal:  Molecules       Date:  2021-05-28       Impact factor: 4.411

7.  Impact of Crystal Habit on the Dissolution Rate and In Vivo Pharmacokinetics of Sorafenib Tosylate.

Authors:  Chi Uyen Phan; Jie Shen; Kaxi Yu; Jianming Mao; Guping Tang
Journal:  Molecules       Date:  2021-06-07       Impact factor: 4.411

Review 8.  Mechanochemistry: A Green Approach in the Preparation of Pharmaceutical Cocrystals.

Authors:  Mizraín Solares-Briones; Guadalupe Coyote-Dotor; José C Páez-Franco; Miriam R Zermeño-Ortega; Carmen Myriam de la O Contreras; Daniel Canseco-González; Alcives Avila-Sorrosa; David Morales-Morales; Juan M Germán-Acacio
Journal:  Pharmaceutics       Date:  2021-05-25       Impact factor: 6.321

Review 9.  The Polymorphism of Drugs: New Approaches to the Synthesis of Nanostructured Polymorphs.

Authors:  Dmitry Chistyakov; Gleb Sergeev
Journal:  Pharmaceutics       Date:  2020-01-01       Impact factor: 6.321

10.  Dissolution Advantage of Nitazoxanide Cocrystals in the Presence of Cellulosic Polymers.

Authors:  Reynaldo Salas-Zúñiga; Christian Rodríguez-Ruiz; Herbert Höpfl; Hugo Morales-Rojas; Obdulia Sánchez-Guadarrama; Patricia Rodríguez-Cuamatzi; Dea Herrera-Ruiz
Journal:  Pharmaceutics       Date:  2019-12-25       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.